This study aimed to explore cell surface biomarkers related to cancer stem cells (CSCs) 
INTRODUCTION
Colorectal cancer is the third most common cause of cancer death in the world [1, 2] . There has been a decline in incidence in the past two decades due to better cancer screening measures [3] . Despite these actions, the morbidity of the disease has not decreased as drastically as those with other types of cancer. This could be changed, however, with the expanding knowledge of the biology of colon cancer cells, particularly with the new subset of cells referred to as cancer stem cells (CSCs). Currently, in addition to surgery, fluorouracil (5-FU) in combination with other anti-cancer agents is used as the standard first line chemotherapy based on NCCN guidelines. Because the heterogeneity of colorectal tumors calls for individualized treatments [4, 5] , understanding the characteristics of colon CSCs may lead to revolutionary findings in targeted therapeutic strategies.
For years, cancer cells were thought to be stochastic in nature and originating from mutations in normal adult cells. However, a sub-population of cells, the CSCs, was found to display stem cell characteristics that influence tumorigenesis. These CSCs have various cancer-promoting characteristics such as self-renewal, www.impactjournals.com/oncotarget differentiation, chemoresistance, and metastatic potential [5] [6] [7] [8] [9] [10] . The exact mechanism of tumorigenicity with which CSCs form cancer is unknown, but the complexity of the microenvironment that cells thrive in is gradually being unveiled. Past scientists have viewed stemness of cells as a combination of intrinsic cell properties as well as circumstantial conditions [11, 12] . CD133 is one of the first stemness markers used to identify CSCs [6, 7] and its expression is a strong predictor of declining prognosis, as high CD133 levels conversely relate to low 5-year overall survival (OS) and disease free survival (DFS) rate in cancer patients [13] [14] [15] . Other putative markers include CD44, CD24, LGR5, ALDH, and CD44v6, though not all are definitive markers that differentiate CSCs from normal adult stem cells, and inconsistent level of these markers are presented across varying stages of the tumor [13, 16] .
CD133 and CD44 are well-recognized stem cell biomarkers expressed in colorectal cancer [3, 17] . High CD133 expression is especially correlated with tumorigenicity, metastasis, and worse prognosis [17] . It has a strong potential as a target for drug therapies, since many colon cancer cell lines will express this marker [18, 19] . The role of CD44, a hyaluronic receptor, is to promote cell-adhesion and assembly of cell surface growth factors, specifically in the maintenance of cell-matrix interactions [17] . When up-regulated, CD44 increases tumor growth and anti-apoptotic property [19] . In Sahlberg's experiment, three colon cancer cell lines HT-29, HCT-116, and DLD-1 expressed different amounts of CD133, CD44, and other markers. Side population cells extracted from the SW480 cell lines showed protein expression of CD44 and other markers of chemoresistance [17, 20, 21] .
Previous reports showed the presence of these biomarkers in many colon cancer cell lines, yet only a few research groups expand their studies to divulge to their exact functions. In this study, we identify that a colon cancer cell line, HCT-116 yield a high percentage of CD44+/CD133+ cells and look further into their relevance to tumor growth property in colon cancer.
RESULTS

Screen for CD44 and CD133 expressed cells in various colorectal cancer cell lines
All cancer cells express varying levels of CD44 and CD133. To delineate CD44 and CD133 expression in colon cancer cells, we used flow cytometry to measure the level of expression of these surface molecules in various colon cancer cell lines. We examined 
Cell cycle analysis
To evaluate the growth capability of cells, both populations of cells were further examined by using cell cycle analysis to evaluate the number of cells represented in each specific replication phase. 
Cell proliferation and colony formation properties
One of the characteristics of stem cells is the formation of spheroidal cell mass. To investigate the growing characteristics of CD44 high /CD133 high and CD44 low / CD133 low cells, both populations of cells were sorted and cultured in serum-free medium (SFM) in low adhesion 6-well plates. The cells were observed with images captured at different time points (0, 6, 8, 20 days) as shown in Figure 5A . It was found that by Day 6 there was a noticeable difference in colony formation ability and size between the Figure 7 shows that in each cell concentration group, the average tumor weight was higher in the CD44 high /CD133 high groups, and this increase was significant in the 10 4 cell injection group.
DISCUSSION
The formation of cancer was once thought to be an accumulation of random mutations in normal adult cells. This is quickly being replaced by a new theory on the organized manner of tumor cell proliferation, particularly with the cancer stem cells [3, 5, 10, 16] . CSCs are a subset of cells that can self-regenerate, differentiate, and facilitate tumor proliferation [5] [6] [7] [8] [9] [10] 25] . The objectives of the study were to identify the common cell surface biomarkers in colon cancer stem cells and the activities relevant to these markers. In this study, CD133 and CD44 expressed cells were found to be highest in the HCT-116 cells, a metastatic colon cancer cell line [26] . Past studies have found a correlation between the percentage of CD133 positive cells in CSCs and tumor aggressiveness [27] [28] [29] , cell invasion [30] , and poor prognosis [31, 32] . The level of CD44 expression is associated with more cancer metastasis and lower overall patient survival [33] . Therefore, the significant levels of CD133 and CD44 found in HCT-116 cells are concurrent with the aggressive cancer properties such as tumor proliferation and metastasis that these cells display in colon cancer. In a recently published paper [17] , high presence of CD44 high /CD133 high cells were observed in both HT-29 and HCT116 cell lines. We did not find high presence of CD44 high /CD133
high cells in HT-29 cell line. One possible explanation might be that instead of using single antibody for CD44 and CD133, researchers in this group used two different specific antibodies for each biomarker, so they were able to pick up more CD44 high /CD133 high cells. Nevertheless, CD133 and CD44 could be strong biomarkers for the identification of CSCs in colon cancer.
The cell cycle analysis revealed that cells that expressed CD133 and CD44 were primarily in the G0/G1 phase, indicating that they have higher growing capability than the cells that were CD44 low /CD133 low . In a study by Kawamoto et al., CD133 cells were found to have faster tumor formation in vitro and in vivo [34] .
Other stem cell markers were observed in the CD44 high /CD133 high cells. CD44 high /CD133 high cells also showed more overexpression of LGR5 and ALDH2. Previous research showed similar expression levels of these biomarkers in CSCs [18, 35] . These markers are also related to the downstream molecular pathways that carry out tumorigenic activities such as Wnt, Notch, and BMP-1 [18, 36] . In addition, CD47 (the integrin-associated protein) is a "don't eat me" molecule of the cell surface immunoglobulin superfamily that is implicated to enable tumors to escape innate immune system surveillance through the evasion of phagocytosis. There were reports that circulating tumor cells (CTCs) overexpressed CD47. Since HCT116 cells are highly metastatic, it might overexpress CD47 to escape the endogenous "eat me" signals. Future study will be perform to investigate the expression of CD47 in CD44 eventually differentiate into a heterogeneous population of tumor cells [3, 6, 7] . However, some researchers have claimed that HCT-116 is a cell line that consists mostly of cells that no longer have the ability to differentiate [25] , and that it is a cell line that is vital to tumor aggressiveness and cell invasion [25, 26, 30] high and CD44 low /CD133 low cells, but may also allow the observation of the timeline of tumor development. Additional studies may be conducted to appreciate the overlapping functions of various CSC biomarkers. We planned to use RNAi technology to down regulate CD133 and CD44 in colon cancer cells to see if it decease the tumorigenic capacity. In addition, we will collect colon cancer patient samples and investigate the expression level of CD133 and CD44. Explore the correlation of expression of CD133/ CD44 and the clinicopathological characteristics.
As the knowledge of colon cancer biology grows, it also exposes a myriad of new targets for novel oncotherapy. In this study, CD44 and CD133 were shown to have significant potential as two biomarkers for colon cancer stem cells. A better understanding of colon cancer stem cell specific biomarkers allow for selective drug toxicity against tumor cells, earlier detection and treatment of colon cancer, and a proactive approach to preventative care for colon cancer. low cells were stained with propidium iodide and analyzed using a flow cytometer (BD Calibur, CA, USA) and ModFit software (Verity, Maine, USA).
MATERIALS AND METHODS
Fluorescence-activated cell sorting (FACS) of cells
Assessment of the expression of cancer stem cell markers by RT-PCR
Measurements of different cancer stem cell markers using quantitative RT-PCR are described previously [22] [23] [24] . Total RNAs were extracted from isolated CD44 high /CD133 high and CD44 low /CD133 low cells using PureLink Kit (Life technologies, MA, USA). RNAs were reversely transcribed to cDNAs (Primescript RT reagent Kit with gDNA Eraser, Takara, China). The primers for human CD44, CD133, ALDH1, ALDH2, Lgr5, c-myc, CK20 and beta-actin (ACTB) were designed using Primer Express and are listed in Table 1 . Expressions of target genes were analyzed by ABI 7500 fast real time PCR System and Power SYBR Green PCR Master Mix (Life Technology, MA, USA). The optimized concentrations for real-time PCR were 0.2 μM for both primers in a 10 μl reaction volume. Human ACTB expression was used as an internal control. Each sample was tested in triplicate. The reaction was as follows: 50°C for 20 sec, 95°C for 10 min, followed by 40 cycles of 95°C for 15 
In vivo tumor formation assay
All animal experiments in this study were approved by the IACUC of the affiliated hospital of Nanjing University of Chinese Medicine. Assorted CD44 , cells per mice, 3 × 7 mice per group) into the right flank of 6-week-old Balb/c nude mice (purchased from SLAC Laboratory animal, Shanghai, China). Animals were sacrificed at 19 days after surgery. Tumor sizes and weights were measured for analysis. 
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